AstraZeneca stock gains on Goldman Sachs target rise
Published on 09/19/2026 at 12:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
AstraZeneca stock (ISIN GB0009895292) traded at 125.23 GBP on September 18, 2026 after Goldman Sachs raised its target to 16,526 pence from 16,300 and kept a Buy rating, while the shares also reacted to recent insider buying and EU drug approvals.
Target lift and insider trade
According to ad hoc news on September 18, 2026, Goldman Sachs lifted its AstraZeneca target to 16,526 pence from 16,300 pence, an increase of 226 pence or about 1.4 percent, and kept a Buy rating.
The same report said Chief Executive Pascal Soriot bought 60,000 shares at 121.02 GBP on September 14, 2026. A separate London-session snapshot showed the stock at 125.23 GBP at 4:28 p.m. local time on September 18, 2026, after a prior close of 122.85 GBP on September 17, 2026.
Q2 2026 figures
On July 27, 2026, AstraZeneca reported Q2 2026 earnings and said revenue for the quarter ended June 30, 2026 was 11.46 billion GBP, up 5.84 percent from 10.83 billion GBP a year earlier.
According to finanzen.ch, earnings per share were 1.20 GBP in Q2 2026 versus 1.18 GBP a year earlier, while the company said the next Q3 2026 numbers are due on October 30, 2026.
Price stays near the range
AstraZeneca shares were still below the 52-week high of 157.30 GBP and above the 52-week low of 107.84 GBP on September 18, 2026. Market capitalization was 194.0 billion GBP in that same London-session snapshot, and 1,680,124 shares changed hands during the day.
AstraZeneca stock at a glance
- Company: AstraZeneca plc
- ISIN: GB0009895292
- Ticker: AZN
- Trading venue: London Stock Exchange
- Price (as of September 18, 2026, 4:28 p.m.): 125.23 GBP
- Market capitalization: 194.0 billion GBP (as of September 18, 2026)
- Sector / Industry: Health Care / Pharmaceuticals
